Acquisition

Diagnostyka to buy 47% of Genomed in $5.1M deal

What's the deal? Diagnostyka, a Polish diagnostics group, has agreed to buy 47.14% of genetics company Genomed for 20.55 million zł (about $5.1 million). Genomed's main shareholders will sell 622,923 shares at 33 zł each, with the deal set to close by December 31, 2026.

What's the endgame? Genomed specialises in genomics and genetic diagnostics. For Diagnostyka, the stake is a potential extension into specialist testing rather than another routine local-lab purchase.

Why now? The agreement follows an active year of dealmaking. Diagnostyka completed eight laboratory-testing acquisitions in the first half of 2026, including in genetics, plus three in diagnostic imaging.

The companies also signed arrangements to keep working with Genomed's key managers, suggesting continuity after close. Genomed said publication of the terms, dated October 14, 2026, had been delayed until the sale agreement was signed on November 18.

What could go wrong? The transaction is not yet complete. Its significance will depend on closing and on how the two companies integrate their capabilities.

The signal: The deal shows Diagnostyka deepening its push beyond routine testing into genetics, a higher-value corner of the diagnostics market — and underlines the pace of consolidation among Polish laboratory operators.

Read more: pb.pl

Image credit: Generated with Gemini

More top stories